IMNMImmunome, Inc.
$19.56+108% 1Y
$19.56
$9.7752 weeks$29.84
IMNM in its own filings
Nothing in IMNM's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
130
Events found in the filings · across 459 filings · the record starts in 2020
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 5, 2026
Most recent filing · Form 8-K
- Record starts
- Sep 1, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountanthistorical
- 2022-10-06
- SEC comment-letter activity13 occurrences
- 2023-11-22
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026Amendment to License Agreement On October 2, 2026, Immunome, Inc. (the “Company”) entered into Amendment No. 4 to License Agreement (the “Amendment”) with Bristol-Myers Squibb Company (“BMS”) to further amend the License Agreement, by and between BMS and the Company (as assignee of Ayala Pharmaceuticals, Inc.), dated …Material agreement entered · Form 8-K
- Aug 11, 2026Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 12, 2026Immunome Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Mar 3, 2026Immunome Reports Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Dec 17, 2025Follow-On Public Offering On December 16, 2025, Immunome, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC and Guggenheim Securities, LLC, as representatives of the several …Other event · Form 8-K
- Dec 15, 2025Phase 3 RINGSIDE Trial Topline Data On December 15, 2025, Immunome, Inc. (the Company, we or our) announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors.Regulation FD disclosure · Form 8-K
- Nov 6, 2025Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks